Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSCW) Debt to Equity (2020 - 2022)

Historic Debt to Equity for Ensysce Biosciences (ENSCW) over the last 3 years, with Q4 2022 value amounting to -$0.03.

  • Ensysce Biosciences' Debt to Equity rose 9361.1% to -$0.03 in Q4 2022 from the same period last year, while for Dec 2022 it was -$0.03, marking a year-over-year increase of 9361.1%. This contributed to the annual value of -$0.03 for FY2022, which is 9361.1% up from last year.
  • According to the latest figures from Q4 2022, Ensysce Biosciences' Debt to Equity is -$0.03, which was up 9361.1% from -$0.34 recorded in Q3 2022.
  • In the past 5 years, Ensysce Biosciences' Debt to Equity registered a high of $1.14 during Q1 2022, and its lowest value of -$5.49 during Q3 2021.
  • Moreover, its 3-year median value for Debt to Equity was -$0.03 (2022), whereas its average is -$0.6.
  • Per our database at Business Quant, Ensysce Biosciences' Debt to Equity tumbled by 494575.86% in 2021 and then soared by 9371.56% in 2022.
  • Quarter analysis of 3 years shows Ensysce Biosciences' Debt to Equity stood at $0.11 in 2020, then tumbled by 580.66% to -$0.54 in 2021, then soared by 93.61% to -$0.03 in 2022.
  • Its Debt to Equity was -$0.03 in Q4 2022, compared to -$0.34 in Q3 2022 and -$0.45 in Q2 2022.